On March 3, 2017, Cuu Long Pharmaceutical Joint Stock Company (DCL) has contributed capital with the State Capital Investment Corporation (SCIC) to establish Benovas Cancer Drugs Joint Stock Company with initial chartered capital of 100 billion VND. In Benovas, Cuu Long Pharmaceutical owns 55% of charter capital, the rest is held by SCIC and other partners.
This is the first cancer drug project in Vietnam. The project started in 2017, with a total investment of 1,000 billion VND for two phases. According to the plan, the time to build and put the factory into operation is about 4 years, however, right in 2017, Cuu Long Pharmaceutical will start importing and distributing products in Vietnam market. Finishing this plan, Cuu Long Pharmaceutical through Benovas, will be the first pharmaceutical company to produce cancer drugs in Vietnam and thereby contribute to lower costs, improve the ability to cure cancer patients in the country.
In the first phase, Benovas will import six types of cancer drugs from its partners and distribute them in Vietnam. These are the drugs that treat common cancers such as cervical cancer, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, colon cancer and small lung cell cancer. Preparations for the distribution of drugs are expected to be completed in the first half of 2017 and are expected to be distributed in Vietnam by the end of 2017.
The next phase, with the transfer of technology from reputable partners in the pharmaceutical industry in the world, Benovas and Cuu Long Pharmaceutical will conduct their own cancer drug production at the company’s factory in Vietnam.
The headquarters of the company is located at: Floor 5, Times Tower building at block 2.6, Le Van Luong street, Nhan Chinh ward, Thanh Xuan district, Hanoi.